secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001558370-22-013057
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q2 net loss $11.5M; IND for IMM-1-104 on track this quarter
-----------------------------------------------------------------------

- Net loss of $11.5M ($0.44 per share) vs $8.0M ($1.61) in Q2 2021.
- Cash and marketable securities $128.1M as of June 30, 2022, down from $150.2M at Dec 31, 2021.
- Management reiterates FY 2022 GAAP operating expense guidance of $55M-$60M.
- IND filing for IMM-1-104 (pan-KRAS/NRAS) expected this quarter; first patient enrollment expected Q4 2022.
- IND application for IMM-6-415 (MEK-IO program) expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000155837022013057/0001558370-22-013057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000155837022013057/imrx-20220810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-013057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer